Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 308

1.

Discordance between Etravirine Phenotype and Genotype-based Predicted Phenotype for Subtype C HIV-1 from First-line Antiretroviral Therapy Failures in South Africa.

McCormick KD, Penrose KJ, Brumme CJ, Harrigan R, Viana RV, Mellors JW, Parikh UM, Wallis CL.

Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02101-19. doi: 10.1128/AAC.02101-19. [Epub ahead of print]

PMID:
32071061
2.

Potential impact and cost-effectiveness of condomless-sex-concentrated PrEP in KwaZulu-Natal accounting for drug resistance.

Phillips A, Cambiano V, Johnson L, Nakagawa F, Homan R, Meyer-Rath G, Rehle T, Tanser F, Moyo S, Shahmanesh M, Castor D, Russell E, Jamieson L, Bansi-Matharu L, Shroufi A, Barnabas R, Parikh UM, Mellors JW, Revill P.

J Infect Dis. 2019 Dec 18. pii: jiz667. doi: 10.1093/infdis/jiz667. [Epub ahead of print]

3.

Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life.

Katusiime MG, Halvas EK, Wright I, Joseph K, Bale MJ, Kirby-McCullough B, Engelbrecht S, Shao W, Hu WS, Cotton MF, Mellors JW, Kearney MF, van Zyl GU.

J Virol. 2020 Jan 31;94(4). pii: e01519-19. doi: 10.1128/JVI.01519-19. Print 2020 Jan 31.

PMID:
31776265
4.

Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors.

Patro SC, Brandt LD, Bale MJ, Halvas EK, Joseph KW, Shao W, Wu X, Guo S, Murrell B, Wiegand A, Spindler J, Raley C, Hautman C, Sobolewski M, Fennessey CM, Hu WS, Luke B, Hasson JM, Niyongabo A, Capoferri AA, Keele BF, Milush J, Hoh R, Deeks SG, Maldarelli F, Hughes SH, Coffin JM, Rausch JW, Mellors JW, Kearney MF.

Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25891-25899. doi: 10.1073/pnas.1910334116. Epub 2019 Nov 27.

PMID:
31776247
5.

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.

Wallis CL, Hughes MD, Ritz J, Viana R, Silva de Jesus C, Saravanan S, van Schalkwyk M, Mngqibisa R, Salata R, Mugyenyi P, Hogg E, Hovind L, Wieclaw L, Gross R, Godfrey C, Collier AC, Grinsztejn B, Mellors JW; A5288 Team.

Clin Infect Dis. 2019 Nov 14. pii: ciz1116. doi: 10.1093/cid/ciz1116. [Epub ahead of print]

PMID:
31724034
6.

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms.

Jacobs JL, Halvas EK, Tosiano MA, Mellors JW.

Front Microbiol. 2019 Oct 15;10:2383. doi: 10.3389/fmicb.2019.02383. eCollection 2019. Review.

7.

T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.

Macatangay BJC, Gandhi RT, Jones RB, Mcmahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR; ACTG A5321 Team.

AIDS. 2020 Jan 1;34(1):15-24. doi: 10.1097/QAD.0000000000002406.

PMID:
31634201
8.

HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus.

Musick A, Spindler J, Boritz E, Pérez L, Crespo-Vélez D, Patro SC, Sobolewski MD, Bale MJ, Reid C, Keele BF, Capoferri A, Shao W, Wiegand A, Simonetti FR, Mellors JW, Hughes SH, Coffin JM, Maldarelli F, Kearney MF.

Front Microbiol. 2019 Oct 1;10:2204. doi: 10.3389/fmicb.2019.02204. eCollection 2019.

9.

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

Gross R, Ritz J, Hughes MD, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Godfrey C, Wallis CL, Mellors JW, Mudhune VO, Badal-Faesen S, Grinsztejn B, Collier AC.

Lancet Digit Health. 2019 May;1(1):e26-e34. doi: 10.1016/S2589-7500(19)30006-8. Epub 2019 May 6.

10.

HIV Proviral Sequence Database: A New Public Database for Near Full-Length HIV Proviral Sequences and Their Meta-Analyses.

Shao W, Shan J, Hu WS, Halvas EK, Mellors JW, Coffin JM, Kearney MF.

AIDS Res Hum Retroviruses. 2020 Jan;36(1):1-3. doi: 10.1089/AID.2019.0214. Epub 2019 Oct 29. No abstract available.

PMID:
31502467
11.

Linked dual-class HIV resistance mutations are associated with treatment failure.

Boltz VF, Shao W, Bale MJ, Halvas EK, Luke B, McIntyre JA, Schooley RT, Lockman S, Currier JS, Sawe F, Hogg E, Hughes MD, Kearney MF, Coffin JM, Mellors JW.

JCI Insight. 2019 Oct 3;4(19). pii: 130118. doi: 10.1172/jci.insight.130118.

12.

HIV-1 DNA decay is faster in children who initiate ART shortly after birth than later.

Veldsman KA, Janse van Rensburg A, Isaacs S, Naidoo S, Laughton B, Lombard C, Cotton MF, Mellors JW, van Zyl GU.

J Int AIDS Soc. 2019 Aug;22(8):e25368. doi: 10.1002/jia2.25368.

13.

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team.

Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29.

PMID:
31371262
14.

HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy.

McManus WR, Bale MJ, Spindler J, Wiegand A, Musick A, Patro SC, Sobolewski MD, Musick VK, Anderson EM, Cyktor JC, Halvas EK, Shao W, Wells D, Wu X, Keele BF, Milush JM, Hoh R, Mellors JW, Hughes SH, Deeks SG, Coffin JM, Kearney MF.

J Clin Invest. 2019 Jul 30;130:4629-4642. doi: 10.1172/JCI126714.

15.

Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.

Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJC, Lalama C, Rinaldo C Jr, Collier A, Godfrey C, Hogg E, Hensel C, Eron JJ, Mcmahon DK, Mellors JW, Tebas P, Gandhi RT; A5321 Study Team.

J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e27-e31. doi: 10.1097/QAI.0000000000002124.

PMID:
31335587
16.

Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, Hogg E, Vecchio A, Mellors JW.

J Clin Invest. 2019 Jul 15;129(8):3339-3346. doi: 10.1172/JCI127413. eCollection 2019 Jul 15.

17.

A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Hiv-Associated Chronic Inflammation.

Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA.

J Infect Dis. 2019 Jul 6. pii: jiz344. doi: 10.1093/infdis/jiz344. [Epub ahead of print]

PMID:
31282542
18.

Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166. doi: 10.1016/j.bbmt.2019.06.033. Epub 2019 Jul 4.

PMID:
31279752
19.

Clones of infected cells arise early in HIV-infected individuals.

Coffin JM, Wells DW, Zerbato JM, Kuruc JD, Guo S, Luke BT, Eron JJ, Bale M, Spindler J, Simonetti FR, Hill S, Kearney MF, Maldarelli F, Wu X, Mellors JW, Hughes SH.

JCI Insight. 2019 Jun 20;4(12). pii: 128432. doi: 10.1172/jci.insight.128432. eCollection 2019 Jun 20.

20.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.

Chimukangara B, Lessells RJ, Rhee SY, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, Abdool Karim SS, de Oliveira T.

EClinicalMedicine. 2019 Mar 18;9:26-34. doi: 10.1016/j.eclinm.2019.03.006. eCollection 2019 Mar.

21.

Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?

Abdel-Massih RC, Mellors JW.

Open Forum Infect Dis. 2019 Apr 20;6(5):ofz196. doi: 10.1093/ofid/ofz196. eCollection 2019 May.

22.

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.

Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, Parikh UM, Abbas UL.

J Int AIDS Soc. 2019 May;22(5):e25282. doi: 10.1002/jia2.25282.

23.

Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.

Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; ACTG 5321 Team.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599. doi: 10.1097/QAI.0000000000002080.

PMID:
31045647
24.

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size.

Rosenbloom DIS, Bacchetti P, Stone M, Deng X, Bosch RJ, Richman DD, Siliciano JD, Mellors JW, Deeks SG, Ptak RG, Hoh R, Keating SM, Dimapasoc M, Massanella M, Lai J, Sobolewski MD, Kulpa DA, Busch MP; Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group.

PLoS Comput Biol. 2019 Apr 12;15(4):e1006849. doi: 10.1371/journal.pcbi.1006849. eCollection 2019 Apr.

25.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

26.

Longitudinal changes in HIV DNA in HIV controllers: what do they mean?

Hsu DC, Mellors JW.

J Int AIDS Soc. 2019 Feb;22(2):e25254. doi: 10.1002/jia2.25254. No abstract available.

27.

Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1.

Zerbato JM, McMahon DK, Sobolewski MD, Mellors JW, Sluis-Cremer N.

Clin Infect Dis. 2019 Nov 13;69(11):1919-1925. doi: 10.1093/cid/ciz108.

28.

Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART.

Bui JK, Cyktor JC, Fyne E, Campellone S, Mason SW, Mellors JW.

PLoS One. 2019 Jan 25;14(1):e0211112. doi: 10.1371/journal.pone.0211112. eCollection 2019.

29.

A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy.

Tosiano MA, Jacobs JL, Shutt KA, Cyktor JC, Mellors JW.

J Clin Microbiol. 2019 Feb 27;57(3). pii: e01714-18. doi: 10.1128/JCM.01714-18. Print 2019 Mar.

30.

Regulatory T cells: the ultimate HIV reservoir?

Rocco J, Mellors JW, Macatangay BJ.

J Virus Erad. 2018 Oct 1;4(4):209-214.

31.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.

Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5342 Protocol Team .

Open Forum Infect Dis. 2018 Oct 20;5(10):ofy242. doi: 10.1093/ofid/ofy242. eCollection 2018 Oct.

32.

Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.

Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S, Mhlanga F, Ramjee G, Mayo AJ, Livant E, Heaps AL, O'Rourke C, Baeten JM; MTN-015 and MTN-020/ASPIRE Study Teams.

Clin Infect Dis. 2019 Jul 18;69(3):523-529. doi: 10.1093/cid/ciy909.

33.

Ongoing HIV Replication During ART Reconsidered.

Kearney MF, Wiegand A, Shao W, McManus WR, Bale MJ, Luke B, Maldarelli F, Mellors JW, Coffin JM.

Open Forum Infect Dis. 2017 Sep 19;4(3):ofx173. doi: 10.1093/ofid/ofx173. eCollection 2017 Summer.

34.

Reply to Suthar et al.

Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW.

J Infect Dis. 2019 Jan 29;219(4):673-674. doi: 10.1093/infdis/jiy558. No abstract available.

35.

Measurement of plasma HIV-1 RNA below the limit of quantification (<20 copies/mL) of commercial assays with the integrase HIV RNA single-copy assay.

Margot N, Koontz D, McCallister S, Mellors JW, Callebaut C.

J Clin Virol. 2018 Nov;108:50-52. doi: 10.1016/j.jcv.2018.09.003. Epub 2018 Sep 10.

PMID:
30240941
36.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

37.

Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapy.

Hong F, Jacobs JL, Aga E, Cillo AR, Fyne E, Koontz DL, Zheng L, Mellors JW.

Virology. 2018 Aug;521:51-57. doi: 10.1016/j.virol.2018.05.018. Epub 2018 Jun 4.

38.

Reply to Kojima and Klausner.

Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW.

Clin Infect Dis. 2018 Oct 15;67(9):1469-1470. doi: 10.1093/cid/ciy345. No abstract available.

39.

Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage.

Jennings C, Wager CG, Scianna SR, Zaccaro DJ, Couzens A, Mellors JW, Coombs RW, Bremer JW.

J Clin Microbiol. 2018 May 25;56(6). pii: e00120-18. doi: 10.1128/JCM.00120-18. Print 2018 Jun.

40.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

Penrose KJ, Brumme CJ, Scoulos-Hanson M, Hamanishi K, Gordon K, Viana RV, Wallis CL, Harrigan PR, Mellors JW, Parikh UM.

Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618762985. doi: 10.1177/2040206618762985.

41.

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.

Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK; A5321 Team.

J Infect Dis. 2018 Jun 20;218(2):234-238. doi: 10.1093/infdis/jiy011.

42.

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults.

Kearney MF, Spindler J, Wiegand A, Shao W, Haubrich R, Riddler S, Lalama CM, Hughes MD, Coffin JM, Mellors JW.

PLoS One. 2018 Jan 25;13(1):e0190438. doi: 10.1371/journal.pone.0190438. eCollection 2018.

43.

Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge.

Veldsman KA, Maritz J, Isaacs S, Katusiime MG, Janse van Rensburg A, Laughton B, Mellors JW, Cotton MF, van Zyl GU.

AIDS. 2018 Mar 13;32(5):629-634. doi: 10.1097/QAD.0000000000001739.

44.

Blood biomarkers of expressed and inducible HIV-1.

Cillo AR, Hong F, Tsai A, Irrinki A, Kaur J, Sloan DD, Follen M, Geleziunas R, Cihlar T, Win SS, Murry JP, Mellors JW.

AIDS. 2018 Mar 27;32(6):699-708. doi: 10.1097/QAD.0000000000001748.

45.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.

Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZ.

Pathog Immun. 2017;2(3):431-445. doi: 10.20411/pai.v2i3.222. Epub 2017 Nov 27.

46.

Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities.

Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW.

Clin Infect Dis. 2018 May 2;66(10):1487-1491. doi: 10.1093/cid/ciy008.

PMID:
29324994
47.

The Argument Against Testing for INSTI Resistance in Treatment Naive Patients.

Veldkamp PJ, Mellors JW, Halvas EK.

Clin Infect Dis. 2018 May 17;66(11):1820-1821. doi: 10.1093/cid/ciy015. No abstract available.

PMID:
29324987
48.

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.

Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW.

J Infect Dis. 2017 Dec 1;216(suppl_9):S851-S856. doi: 10.1093/infdis/jix409. Review.

49.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

50.

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.

Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB.

PLoS Pathog. 2017 Sep 20;13(9):e1006629. doi: 10.1371/journal.ppat.1006629. eCollection 2017 Sep.

Supplemental Content

Loading ...
Support Center